We understand that covered entities are extremely cautious about disclosing any 340B Program information related to their facility, patients, and contract pharmacies. The specificity of the information Kalderos is requesting has been authorized by our pharmaceutical manufacturer clients. Please find letters authorizing Kalderos to contact covered entities on behalf of our clients below:

Did this answer your question?